MSD’s verubecestat fails again in Alzheimer’s trial
PharmaTimes | February 13, 2018
Five new medicines are to be funded by the NHS in Scotland, bringing new treatment options for cancer, multiple sclerosis and rheumatoid arthritis, as well as a new contraceptive. The Scottish Medicines Consortium (SMC) has accepted MSD’s Keytruda (pembrolizumab) for the treatment of advanced bladder cancer following consideration through SMC’s Patient and Clinician Engagement (PACE) process for medicines used to treat very rare and end of life conditions.